Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free IBT Stock Alerts

International Biotechnology (IBT) Competitors

International Biotechnology logo
GBX 1,085 -15.00 (-1.36%)
As of 08/11/2026 12:01 PM Eastern
Compare

IBT vs. WWH, BHMG, ASL, JMG, and TMPL

Should you buy International Biotechnology stock or one of its competitors? International Biotechnology's main competitors and comparable companies include Worldwide Healthcare (WWH), BH Macro GBP (BHMG), Aberforth Smaller Companies Trust (ASL), JPMorgan Emerging Markets (JMG), and Temple Bar (TMPL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does International Biotechnology compare to Worldwide Healthcare?

International Biotechnology (LON:IBT) and Worldwide Healthcare (LON:WWH) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

International Biotechnology has a beta of 0.47368002, indicating that its share price is 53% less volatile than the broader market. Comparatively, Worldwide Healthcare has a beta of 0.262, indicating that its share price is 74% less volatile than the broader market.

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 7.9% of Worldwide Healthcare shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by insiders. Comparatively, 0.2% of Worldwide Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Worldwide Healthcare pays an annual dividend of GBX 2.40 per share and has a dividend yield of 0.6%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Worldwide Healthcare pays out 9.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Worldwide Healthcare has a net margin of 85.46% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat Worldwide Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Worldwide Healthcare 85.46%8.01%-2.02%

Worldwide Healthcare has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Worldwide Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.42£37.91M£241.734.49
Worldwide Healthcare£118.16M11.84£227.88M£26.7014.61

In the previous week, Worldwide Healthcare had 1 more articles in the media than International Biotechnology. MarketBeat recorded 2 mentions for Worldwide Healthcare and 1 mentions for International Biotechnology. Worldwide Healthcare's average media sentiment score of 1.31 beat International Biotechnology's score of 0.67 indicating that Worldwide Healthcare is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
International Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Worldwide Healthcare
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Worldwide Healthcare beats International Biotechnology on 9 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to BH Macro GBP?

International Biotechnology (LON:IBT) and BH Macro GBP (LON:BHMG) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

BH Macro GBP has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than BH Macro GBP, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.42£37.91M£241.734.49
BH Macro GBP£277.60M4.98£53.77M£45.689.36

International Biotechnology has a net margin of 82.27% compared to BH Macro GBP's net margin of 54.44%. International Biotechnology's return on equity of 27.35% beat BH Macro GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
BH Macro GBP 54.44%7.42%-0.31%

International Biotechnology has a beta of 0.47368002, meaning that its stock price is 53% less volatile than the broader market. Comparatively, BH Macro GBP has a beta of 0.1291358, meaning that its stock price is 87% less volatile than the broader market.

6.7% of International Biotechnology shares are held by institutional investors. Comparatively, 1.6% of BH Macro GBP shares are held by institutional investors. 1.1% of International Biotechnology shares are held by company insiders. Comparatively, 0.1% of BH Macro GBP shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, International Biotechnology had 1 more articles in the media than BH Macro GBP. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for BH Macro GBP. International Biotechnology's average media sentiment score of 0.67 beat BH Macro GBP's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
BH Macro GBP Neutral

Summary

International Biotechnology beats BH Macro GBP on 9 of the 13 factors compared between the two stocks.

How does International Biotechnology compare to Aberforth Smaller Companies Trust?

International Biotechnology (LON:IBT) and Aberforth Smaller Companies Trust (LON:ASL) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Aberforth Smaller Companies Trust pays an annual dividend of GBX 46.80 per share and has a dividend yield of 2.7%. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Aberforth Smaller Companies Trust pays out 40.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

Aberforth Smaller Companies Trust has higher revenue and earnings than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than Aberforth Smaller Companies Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Biotechnology£78.01M4.42£37.91M£241.734.49
Aberforth Smaller Companies Trust£94.68M14.09£255.01M£115.7814.94

International Biotechnology has a net margin of 82.27% compared to Aberforth Smaller Companies Trust's net margin of 63.47%. International Biotechnology's return on equity of 27.35% beat Aberforth Smaller Companies Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
International Biotechnology82.27% 27.35% 3.57%
Aberforth Smaller Companies Trust 63.47%6.52%11.67%

International Biotechnology has a beta of 0.47368002, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Aberforth Smaller Companies Trust has a beta of 1.4412928, suggesting that its stock price is 44% more volatile than the broader market.

In the previous week, International Biotechnology had 1 more articles in the media than Aberforth Smaller Companies Trust. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Aberforth Smaller Companies Trust. International Biotechnology's average media sentiment score of 0.67 beat Aberforth Smaller Companies Trust's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
International Biotechnology Positive
Aberforth Smaller Companies Trust Neutral

6.7% of International Biotechnology shares are owned by institutional investors. Comparatively, 13.1% of Aberforth Smaller Companies Trust shares are owned by institutional investors. 1.1% of International Biotechnology shares are owned by company insiders. Comparatively, 0.4% of Aberforth Smaller Companies Trust shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

International Biotechnology beats Aberforth Smaller Companies Trust on 8 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to JPMorgan Emerging Markets?

JPMorgan Emerging Markets (LON:JMG) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

14.8% of JPMorgan Emerging Markets shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.0% of JPMorgan Emerging Markets shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

JPMorgan Emerging Markets has higher earnings, but lower revenue than International Biotechnology. International Biotechnology is trading at a lower price-to-earnings ratio than JPMorgan Emerging Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Emerging Markets£56.31M23.64£80.10M£4.6329.33
International Biotechnology£78.01M4.42£37.91M£241.734.49

JPMorgan Emerging Markets has a net margin of 95.26% compared to International Biotechnology's net margin of 82.27%. International Biotechnology's return on equity of 27.35% beat JPMorgan Emerging Markets' return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Emerging Markets95.26% 19.61% 1.55%
International Biotechnology 82.27%27.35%3.57%

In the previous week, International Biotechnology had 1 more articles in the media than JPMorgan Emerging Markets. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for JPMorgan Emerging Markets. International Biotechnology's average media sentiment score of 0.67 beat JPMorgan Emerging Markets' score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Emerging Markets Neutral
International Biotechnology Positive

JPMorgan Emerging Markets pays an annual dividend of GBX 1.95 per share and has a dividend yield of 1.4%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. JPMorgan Emerging Markets pays out 42.1% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. International Biotechnology is clearly the better dividend stock, given its higher yield and lower payout ratio.

JPMorgan Emerging Markets has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.47368002, meaning that its share price is 53% less volatile than the broader market.

Summary

International Biotechnology beats JPMorgan Emerging Markets on 9 of the 15 factors compared between the two stocks.

How does International Biotechnology compare to Temple Bar?

Temple Bar (LON:TMPL) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

10.7% of Temple Bar shares are held by institutional investors. Comparatively, 6.7% of International Biotechnology shares are held by institutional investors. 0.2% of Temple Bar shares are held by insiders. Comparatively, 1.1% of International Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Temple Bar has a beta of 1.155, meaning that its share price is 16% more volatile than the broader market. Comparatively, International Biotechnology has a beta of 0.47368002, meaning that its share price is 53% less volatile than the broader market.

Temple Bar has higher revenue and earnings than International Biotechnology. Temple Bar is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Temple Bar£281.60M4.63£154.90M£97.004.40
International Biotechnology£78.01M4.42£37.91M£241.734.49

Temple Bar pays an annual dividend of GBX 14.25 per share and has a dividend yield of 3.3%. International Biotechnology pays an annual dividend of GBX 31.81 per share and has a dividend yield of 2.9%. Temple Bar pays out 14.7% of its earnings in the form of a dividend. International Biotechnology pays out 13.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

International Biotechnology has a net margin of 82.27% compared to Temple Bar's net margin of 82.15%. Temple Bar's return on equity of 27.93% beat International Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Temple Bar82.15% 27.93% 7.08%
International Biotechnology 82.27%27.35%3.57%

In the previous week, International Biotechnology had 1 more articles in the media than Temple Bar. MarketBeat recorded 1 mentions for International Biotechnology and 0 mentions for Temple Bar. International Biotechnology's average media sentiment score of 0.67 beat Temple Bar's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Temple Bar Neutral
International Biotechnology Positive

Summary

Temple Bar beats International Biotechnology on 8 of the 15 factors compared between the two stocks.

Get International Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IBT vs. The Competition

Export
MetricInternational BiotechnologyCapital Markets IndustryFinance SectorLON Exchange
Market Cap£345.06M£5.60B£14.04B£2.88B
Dividend Yield2.87%7.40%5.89%6.09%
P/E Ratio4.4938.1329.21368.35
Price / Sales4.421,229.80510.7583,691.32
Price / Cash155.7448.2838.6827.89
Price / Book1.423.703.687.32
Net Income£37.91M£417.15M£1.31B£5.89B
7 Day Performance3.33%0.35%0.02%1.05%
1 Month Performance-3.98%0.40%0.95%2.50%
1 Year Performance66.41%8.12%12.23%69.40%

International Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IBT
International Biotechnology
N/AGBX 1,085
-1.4%		N/A+66.4%£345.06M£78.01M4.49N/A
WWH
Worldwide Healthcare
N/AGBX 381
+0.8%		N/A+25.8%£1.37B£118.16M14.27N/A
BHMG
BH Macro GBP
N/AGBX 419.50
-0.4%		N/A+9.2%£1.34B£277.60M9.18N/A
ASL
Aberforth Smaller Companies Trust
N/AGBX 1,732
+1.4%		N/A+12.0%£1.34B£94.68M14.96N/A
JMG
JPMorgan Emerging Markets
N/AGBX 135.80
-0.9%		N/A+13.2%£1.33B£56.31M29.33N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:IBT) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
$8B is moving in... are you?
Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...
Awesomely | Sponsoredtc pixel